List of Excipients in Branded Drug DEFERASIROX ORAL GRANULES

Generic Drugs Containing DEFERASIROX ORAL GRANULES

Company	Ingredient	NDC	Excipient
EPIC PHARMA LLC	deferasirox	42806-371	CELLULOSE, MICROCRYSTALLINE
EPIC PHARMA LLC	deferasirox	42806-371	CROSPOVIDONE
EPIC PHARMA LLC	deferasirox	42806-371	MAGNESIUM STEARATE
EPIC PHARMA LLC	deferasirox	42806-371	POLOXAMER 188
EPIC PHARMA LLC	deferasirox	42806-371	POVIDONE

What are the Most Frequently-Used Excipients in DEFERASIROX ORAL GRANULES?

# Of NDCs	Excipient
2	CELLULOSE, MICROCRYSTALLINE
2	CROSPOVIDONE
2	MAGNESIUM STEARATE
2	POLOXAMER 188
2	POVIDONE

Deferasirox Oral Granules: Excipient Strategy, Patent Exposure, and Commercial Opportunities

Last updated: August 23, 2026

Deferasirox oral granules are a differentiated delivery format for chronic iron-overload treatment. The commercial opportunity is concentrated in pediatric patients, patients with dysphagia, caregivers who need flexible administration, and markets where tablets or dispersible tablets have poor adherence. The principal formulation challenge is balancing palatability, dose uniformity, powder flow, chemical stability, and compatibility with soft foods.

The U.S. reference product is Jadenu Sprinkle, a granule formulation of deferasirox administered by sprinkling the dose onto soft food. Deferasirox is a small-molecule iron chelator approved for transfusional iron overload and non-transfusion-dependent thalassemia in specified patient populations (U.S. Food and Drug Administration [FDA], 2020; Novartis Pharmaceuticals Corporation, 2020).

What is the commercial role of deferasirox oral granules?

Deferasirox oral granules address administration barriers that remain with tablets and dispersible tablets.

Product type	Administration	Primary commercial benefit	Main limitation
Exjade dispersible tablets	Dispersed in liquid before administration	Established product and dose strengths	Preparation burden, taste, administration volume
Jadenu film-coated tablets	Swallowed whole	Lower administration burden than Exjade	Dysphagia and pediatric-use limitations
Jadenu Sprinkle granules	Sprinkled onto soft food	Flexible administration and improved suitability for children	Taste, dose handling, packet waste, excipient constraints
Generic deferasirox tablets	Usually swallowed whole	Lower price	Limited differentiation and less pediatric flexibility

Jadenu Sprinkle is supplied in 90 mg and 180 mg packets. The product is intended for oral administration with soft foods such as applesauce or yogurt, according to product labeling. The granules are not intended to be chewed or crushed, and administration instructions are part of the product's safety and usability profile (Novartis Pharmaceuticals Corporation, 2020).

The strongest commercial positioning is not broad substitution across all deferasirox users. It is targeted conversion of patients who have difficulty swallowing tablets, cannot reliably prepare dispersible tablets, or require caregiver-administered dosing.

Which patients create the largest opportunity for oral granules?

The highest-value patient segments are those in which administration failure directly affects iron-burden control.

Pediatric transfusion-dependent patients

Children with beta-thalassemia, sickle cell disease, Diamond-Blackfan anemia, and other chronic transfusion conditions are the clearest target population. Chronic chelation requires sustained adherence over years. A granule product can reduce the mechanical barrier associated with tablets and the preparation burden associated with dispersible formulations.

Pediatric opportunities include:

• Caregiver-administered dosing.
• Patients transitioning from liquid or dispersed formulations.
• Children requiring dose adjustments based on body weight and serum ferritin.
• Patients who reject strongly flavored suspensions or dispersed tablets.
• Use in home, school, and travel settings.

Patients with dysphagia

Adults with swallowing difficulties may also benefit, particularly older patients with hematologic disorders or comorbid neurologic disease. The commercial value is smaller than in pediatrics but can support hospital formulary and specialty-pharmacy adoption.

Patients requiring dose titration

Deferasirox dosing is adjusted according to transfusion burden, serum ferritin, liver iron concentration, renal function, and tolerability. The 90 mg and 180 mg packet strengths provide flexibility, but they do not eliminate the need for multiple packets in higher-dose patients.

A differentiated product could compete through smaller dose increments, lower-strength packets, or multi-dose dispensing systems. Any such strategy would require a new product presentation and supporting dose-uniformity data.

What excipients are used in deferasirox oral granules?

The reference granule formulation uses conventional pharmaceutical excipients associated with powder processing, granule integrity, flow, compression avoidance, and oral administration. The exact qualitative and quantitative composition should be taken from the current approved product label and regulatory filings.

Public labeling for deferasirox products identifies excipient classes including:

• Microcrystalline cellulose.
• Crospovidone.
• Povidone.
• Sodium lauryl sulfate.
• Colloidal silicon dioxide.
• Lactose monohydrate.
• Magnesium stearate.
• Film-coating or capsule-related materials, where applicable.

The formulation is not simply a tableting blend converted into a sachet. Oral granules require a different control strategy because the product must remain free-flowing, doseable, physically stable in a packet, and acceptable when placed directly on food.

Excipient function	Candidate materials	Commercial and technical considerations
Diluent or carrier	Microcrystalline cellulose, lactose monohydrate, mannitol	Controls bulk density, mouthfeel, packet fill, and dose size
Binder	Povidone, hydroxypropyl cellulose	Affects granule strength and dissolution
Disintegrant	Crospovidone, croscarmellose sodium	Supports dispersion and wetting
Surfactant	Sodium lauryl sulfate, poloxamer	Improves wetting of poorly soluble drug; may affect taste and gastrointestinal tolerability
Glidant	Colloidal silicon dioxide	Improves flow and reduces packet-filling variability
Lubricant	Magnesium stearate, sodium stearyl fumarate	Excess levels can impair wetting and dissolution
Taste modifier	Sucralose, acesulfame potassium, flavor systems	May reduce bitterness but can introduce stability and regulatory complexity
Food-compatible matrix	Mannitol, isomalt, maltodextrin	Can improve mouthfeel and reduce lactose exposure

How should an excipient strategy address deferasirox’s formulation risks?

Deferasirox has low aqueous solubility and pH-dependent dissolution behavior. Excipient selection therefore affects wetting, dispersion, dissolution, and ultimately exposure. The goal is not maximum dissolution at any single pH. The formulation must deliver reproducible performance across the administration conditions specified in the label.

Solubility and wetting

A surfactant such as sodium lauryl sulfate can improve wetting of hydrophobic drug particles. Its level must be controlled because high surfactant concentrations may produce unpleasant taste, foaming, gastrointestinal irritation, or changes in dissolution after storage.

Particle-size engineering may reduce the need for high surfactant loading. Micronized or controlled-size deferasirox can improve surface area, but smaller particles also increase electrostatic charging, cohesion, dusting, and segregation risk.

Taste and mouthfeel

Taste is a major commercial constraint. Deferasirox can produce a bitter or metallic oral sensation. Granules deposited on soft food may reduce direct contact with the tongue, but the drug can still be released during chewing or swallowing.

A practical taste strategy is to combine:

1. Drug particle coating or lipid/polymer layering.
2. Low-moisture granulation.
3. A compatible sweetener or flavor system.
4. Food-based administration instructions that limit chewing.

A fully taste-masked multiparticulate system may be commercially attractive but could create new manufacturing and regulatory burdens. Polymer-coated particles must demonstrate adequate drug release, stability, content uniformity, and reproducible performance after contact with food.

Lactose management

Lactose is used in several deferasirox products as a diluent or bulking agent. It provides low cost and established regulatory acceptability, but lactose-free positioning could create a differentiation opportunity for patients with lactose intolerance or for markets that favor lactose-free pediatric products.

Replacing lactose with mannitol, microcrystalline cellulose, or another carrier would affect:

• Bulk density.
• Granule strength.
• Mouthfeel.
• Hygroscopicity.
• Packet fill weight.
• Dissolution.
• Manufacturing yield.

A lactose-free formulation would need to demonstrate that the substitution does not change bioavailability or administration performance.

Flow and packet filling

Granules are vulnerable to segregation when the active ingredient and excipients have different particle sizes or densities. This is particularly important for small-dose packets and multi-strength packaging.

Critical quality attributes include:

• Assay and content uniformity.
• Particle-size distribution.
• Hausner ratio and Carr index.
• Angle of repose.
• Moisture content.
• Packet fill-weight variation.
• Dust generation.
• Electrostatic behavior.
• Reconstitution or dispersion performance on soft food.

Colloidal silicon dioxide may improve flow, but overuse can increase dust and alter dissolution. A controlled granulation endpoint is usually more important than simply increasing glidant concentration.

What formulations are protected by deferasirox patents?

Deferasirox patent protection has historically covered the active compound, pharmaceutical compositions, dosage forms, and methods of treating iron overload. The earliest compound-level and composition-level protection is materially older than the oral granule product. The commercial risk therefore depends on the jurisdiction and on whether later formulation or manufacturing patents remain enforceable.

Protection category	Relevance to oral granules	Expected competitive exposure
Deferasirox active compound	Historically protected the molecule	Core protection is substantially aged or expired in major markets
Pharmaceutical composition	May cover salts, excipient combinations, or dosage forms	Depends on claim scope and jurisdiction
Dispersible tablet technology	Relevant to Exjade-type products	Generally offers limited protection against independently designed granules
Film-coated tablet formulation	Relevant to Jadenu tablets	May not block a granule product unless claims are broad
Oral granule or sprinkle formulation	Potentially relevant to Jadenu Sprinkle	Highest importance for direct granule competition
Manufacturing process	Can cover granulation, coating, milling, or blending	May create a process barrier even where product claims are narrow
Method of use	May cover treatment of transfusional or non-transfusion-dependent iron overload	Enforcement depends on label overlap and induced-infringement facts

An entrant should not assume that expiration of the original deferasirox compound patent eliminates all formulation risk. The relevant analysis requires review of the current U.S. Orange Book, issued patents, patent-term adjustments, terminal disclaimers, litigation records, and claim scope in each target jurisdiction (FDA, 2024a).

What is the Orange Book status of deferasirox oral granules?

The Orange Book is the primary U.S. source for listed patents and regulatory exclusivity associated with approved drug products. Deferasirox tablets and granule products must be evaluated separately because the reference products may have different applications, strengths, dosage forms, and listed patents.

For a generic oral granule applicant, the relevant questions are:

• Is the proposed product an ANDA or does it require a 505(b)(2) application?
• Is the reference product specifically listed as a granule or sprinkle dosage form?
• Are any patents listed against the granule product?
• Has pediatric exclusivity extended a listed patent term?
• Is a Paragraph IV certification required?
• Does the proposed label overlap patented methods of use?
• Are the product characteristics sufficiently similar for an ANDA?

A product that differs materially in excipient composition, particle engineering, food administration, or release behavior may face a 505(b)(2) pathway rather than a conventional ANDA pathway. The regulatory classification depends on the proposed product and the reference product, not on the active ingredient alone (FDA, 2024b).

When does deferasirox lose exclusivity?

Deferasirox’s exclusivity profile has several layers.

Active-ingredient protection

The original active-ingredient protection is substantially older than the Jadenu Sprinkle formulation. This creates a foundation for generic deferasirox competition, particularly in tablet dosage forms.

Regulatory exclusivity

Regulatory exclusivity is separate from patent protection. Pediatric exclusivity, orphan-drug exclusivity, or new-indication exclusivity can delay approval of an otherwise approvable generic product. The exact duration depends on the applicable approval and exclusivity records.

Formulation protection

A newer granule formulation may have later-expiring protection than the active compound. Formulation protection is commercially relevant only if the claims cover the competing product and remain enforceable in the market of interest.

Market reality

The likely sequence is:

1. Generic tablets compete primarily on price.
2. Granule products retain a convenience and pediatric-use advantage.
3. A generic granule entrant pressures price only if it can match administration instructions, packet strengths, taste, and regulatory substitutability.
4. A 505(b)(2) product can compete through a differentiated excipient or delivery profile but may incur higher development and clinical costs.

Which companies are challenging deferasirox products?

Generic competition exists for deferasirox tablets and other oral presentations in several markets. The competitive field includes generic manufacturers capable of producing immediate-release solid oral dosage forms, specialty pharmaceutical companies targeting hematology, and contract manufacturers with sachet or stick-pack capabilities.

Direct competition in oral granules is more demanding than tablet competition because the entrant must reproduce or improve:

• Low-dose content uniformity.
• Granule flow.
• Food compatibility.
• Taste performance.
• Packet integrity.
• Child-resistant and caregiver-friendly packaging.
• Long-term stability.
• Label-specific administration instructions.

Publicly documented Paragraph IV challenges should be assessed through FDA approval records, the Orange Book, Abbreviated New Drug Application litigation reports, and federal court dockets. A general statement that a company markets generic deferasirox tablets does not establish a Paragraph IV challenge to the granule formulation.

What commercial opportunities exist for new deferasirox excipient systems?

Lactose-free oral granules

A lactose-free product could target patients with lactose intolerance and institutions seeking simplified pediatric excipient profiles. Mannitol and microcrystalline cellulose are practical replacement candidates, but the resulting product may have a larger packet volume or different mouthfeel.

Taste-masked multiparticulates

A polymer-coated or lipid-coated granule could improve acceptability without changing the active ingredient. The commercial value is highest in children who discontinue therapy because of taste.

The main risks are delayed release, incomplete drug liberation after administration on food, coating variability, and higher manufacturing cost.

Smaller packet strengths

Lower-strength packets could improve weight-based dosing and reduce the need to open multiple packets. This may have particular value in young children and patients at the lower end of the approved dosing range.

The tradeoff is increased packaging complexity and higher per-milligram packaging cost.

Unit-dose stick packs

Stick packs may improve portability and caregiver handling compared with traditional sachets. They also create opportunities for calendar packaging, adherence tracking, and specialty-pharmacy distribution.

The principal technical risks are powder bridging, electrostatic loss, seal contamination, and moisture ingress.

Co-packaged adherence systems

A commercial package could combine oral granules with dosing calendars, ferritin-monitoring reminders, or caregiver instructions. These elements are less likely to create durable patent barriers but can improve specialty-pharmacy differentiation.

Global pediatric presentations

Markets with high thalassemia prevalence may favor granules over tablets because of pediatric dosing and local administration practices. Commercial deployment must account for different food customs, labeling requirements, climate conditions, and excipient restrictions.

How strong is the patent estate for deferasirox oral granules?

The patent estate is strongest where claims cover a specific granule architecture, coating system, excipient ratio, particle-size distribution, or manufacturing process. It is weaker where protection depends only on broad use of deferasirox in an oral solid dosage form.

A practical strength assessment should score five dimensions:

Dimension	Strong position	Weak position
Claim scope	Covers product attributes that competitors must use	Easy to design around
Patent term	Extends materially beyond generic tablet entry	Near expiration
Detectability	Product infringement can be proven analytically	Requires confidential process evidence
Regulatory linkage	Listed in the Orange Book	Not listed or not relevant to ANDA pathway
Commercial necessity	Claimed feature is important for taste or performance	Feature has low clinical or commercial value

Manufacturing-process patents may have higher practical value than broad excipient claims if the process delivers reliable content uniformity and flow at commercial scale. They also may be harder to detect through routine product testing, which complicates enforcement.

What litigation and settlement issues affect generic entry?

Potential litigation can arise from:

• Paragraph IV certification against listed formulation patents.
• Patent infringement claims involving granule composition or manufacturing.
• Induced infringement based on food-administration instructions.
• Hatch-Waxman litigation over the correct reference product.
• Regulatory disputes over whether a proposed granule product is therapeutically equivalent.
• Trade-secret disputes involving granulation or coating processes.

A settlement could establish a licensed entry date, but no settlement term should be assumed without a filed agreement, court order, or publicly disclosed transaction. No major third-party licensing arrangement is established solely by the existence of the Jadenu Sprinkle product. The product was developed within the Novartis deferasirox franchise, and any current license or supply arrangement would require review of transaction filings and commercial agreements.

How does deferasirox oral granules compare with competing iron chelators?

Drug	Dosage forms	Key administration advantage	Commercial constraint
Deferasirox	Dispersible tablets, film-coated tablets, oral granules	Once-daily oral dosing and granule flexibility	Renal and hepatic monitoring; gastrointestinal tolerability
Deferiprone	Tablets and oral solution	Oral option with liquid availability	Neutropenia/agranulocytosis monitoring
Deferoxamine	Injectable	Established chelation efficacy	Parenteral administration and infusion burden

Deferasirox granules compete primarily on convenience and adherence rather than on a new chelation mechanism. A better excipient system can improve persistence, but it does not remove the need for monitoring renal function, hepatic function, blood counts, and iron burden under the approved labeling (FDA, 2020).

What generic launch scenarios exist for deferasirox oral granules?

Scenario 1: Tablet-led generic erosion

Generic tablets enter first and reduce the price of conventional deferasirox. Granules retain a premium in pediatric and dysphagia segments.

Scenario 2: Direct generic granule entry

A manufacturer develops an ANDA or 505(b)(2) product that closely matches the reference granule presentation. Price competition expands into specialty and pediatric channels.

Scenario 3: Differentiated 505(b)(2) product

A company introduces lactose-free, taste-masked, lower-strength, or modified-packet granules. Regulatory and development costs are higher, but the product can avoid direct price parity.

Scenario 4: Regional specialty launch

A manufacturer focuses on countries with high transfusion-dependent thalassemia prevalence and limited access to branded granules. Local manufacturing, climate-stable packaging, and low-cost excipients become more important than premium taste technology.

Key Takeaways

• Deferasirox oral granules have their strongest opportunity in pediatric patients, caregivers, and patients unable to swallow tablets.
• The most valuable excipient functions are wetting, taste reduction, powder flow, content uniformity, and food compatibility.
• Lactose-free and taste-masked formulations offer the clearest product-differentiation paths.
• Core deferasirox compound protection is older than the granule product, so later formulation and manufacturing rights drive direct competition risk.
• Generic tablet entry does not automatically create equivalent competition for oral granules.
• Direct granule competition requires control of packet filling, particle-size distribution, moisture, taste, stability, and administration instructions.
• The U.S. Orange Book and current patent records must be reviewed product by product because deferasirox tablets and granules may have different regulatory and patent profiles.
• Deferasirox is a small molecule, so biosimilar risk is not relevant. Generic and 505(b)(2) competition are the applicable pathways.
• The highest-value commercial asset is a granule platform that improves adherence without materially changing exposure or administration requirements.

FAQs About Deferasirox Oral Granules

Are deferasirox oral granules suitable for children?

Yes. The granule format is particularly suitable for children who cannot swallow tablets, provided administration follows the approved labeling and prescribed dose.

Can deferasirox granules be mixed with water?

The administration method depends on the specific product label. Jadenu Sprinkle is designed to be sprinkled onto soft food rather than prepared as a conventional liquid suspension.

Is lactose-free deferasirox a viable product opportunity?

Yes. A lactose-free product could differentiate through excipient positioning, but it would require comparative dissolution, stability, bioavailability, and patient-acceptability support.

Would a generic deferasirox tablet be automatically substitutable for oral granules?

No. Substitutability depends on dosage form, regulatory approval, therapeutic-equivalence findings, pharmacy law, and the applicable reference product.

Do deferasirox oral granules face biosimilar competition?

No. Deferasirox is a chemically synthesized small molecule. Competition is expected through generic ANDA products, 505(b)(2) products, formulation improvements, and regional branded alternatives.

References

1. U.S. Food and Drug Administration. (2020). Jadenu Sprinkle: Deferasirox granules for oral use prescribing information. U.S. Department of Health and Human Services.

2. U.S. Food and Drug Administration. (2024a). Approved drug products with therapeutic equivalence evaluations: Orange Book. U.S. Department of Health and Human Services.

3. U.S. Food and Drug Administration. (2024b). Abbreviated new drug application submissions: Refuse-to-receive standards. U.S. Department of Health and Human Services.

4. Novartis Pharmaceuticals Corporation. (2020). Jadenu Sprinkle (deferasirox) granules for oral use. DailyMed, National Library of Medicine.

5. U.S. Food and Drug Administration. (2024c). Deferasirox drug label and regulatory information. Drugs@FDA, U.S. Department of Health and Human Services.